- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Bioversys beginnt zulassungsrelevante Studie mit Hoffnungsträger BV100 | 1 | cash | ||
| Do | BioVersys initiates phase 3 trial for BV100 antibiotic candidate | 3 | Investing.com | ||
| BIOVERSYS Aktie jetzt für 0€ handeln | |||||
| Do | BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update | 89 | GlobeNewswire (Europe) | Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission... ► Artikel lesen | |
| Do | Adhoc: BioVersys AG: BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update | 1.113 | EQS Group (EN) | BioVersys AG / Key word(s): Study
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update 11-Dec-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to... ► Artikel lesen | |
| 10.11. | BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network | 1 | GlobeNewswire (USA) | ||
| 10.11. | Adhoc: BioVersys AG: BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network | 1.061 | EQS Group (EN) | BioVersys AG / Key word(s): Study/Funds
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network 10-Nov-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 06.11. | Adhoc: BioVersys AG: Bioversys announces first subjects dosed in Phase 1 clinical trial of BV100 in China | 1.594 | EQS Group (EN) | BioVersys AG / Key word(s): Study
Bioversys announces first subjects dosed in Phase 1 clinical trial of BV100 in China06-Nov-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 05.11. | BioVersys AG: Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york | 334 | EQS Group (EN) | BioVersys AG
/ Key word(s): Conference
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york 05.11.2025 / 07:00 CET/CEST
Basel, Switzerland. November... ► Artikel lesen | |
| 03.11. | BioVersys AG: Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro | 295 | EQS Group (EN) | BioVersys AG
/ Key word(s): Personnel
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro... ► Artikel lesen | |
| 10.09. | Adhoc: BioVersys AG: Bioversys reports corporate highlights and key financials for the first half 2025 | 2.401 | EQS Group (EN) | BioVersys AG / Key word(s): Half Year Results
Bioversys reports corporate highlights and key financials for the first half 2025 10-Sep-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 29.08. | BioVersys AG: Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call | 436 | EQS Group (EN) | BioVersys AG
/ Key word(s): Half Year Results
Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call 29.08.2025 / 07:00... ► Artikel lesen | |
| 27.08. | Adhoc: BioVersys AG: BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis | 1.031 | EQS Group (EN) | BioVersys AG / Key word(s): Regulatory Admission
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis 27-Aug-2025... ► Artikel lesen | |
| 03.07. | BioVersys and Shionogi agree to develop ansamycin leads | 9 | Pharmaceutical Technology | ||
| 02.07. | AMR-Firma BioVersys kooperiert mit Shionogi | 4 | transkript.de | ||
| 02.07. | Shionogi puts up to $600m behind BioVersys antibiotics | 5 | pharmaphorum | ||
| 02.07. | Adhoc: BioVersys AG: BioVersys And Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate | 1.855 | EQS Group (EN) | BioVersys AG / Key word(s): Agreement/Partnership
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL... ► Artikel lesen | |
| 30.06. | Adhoc: Bioversys AG: Bioversys Announces Results From Its Annual General Meeting Of Shareholders | 827 | EQS Group (EN) | BioVersys AG / Key word(s): AGMEGM
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS 30-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 03.06. | Adhoc: BioVersys AG: BioVersys publishes Invitation to its Annual General Meeting of Shareholders 2025 | 3.106 | EQS Group (EN) | BioVersys AG / Key word(s): AGMEGM
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025 03-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 02.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 02.05.2025 | 8.285 | Xetra Newsboard | The following instruments on XETRA do have their first trading 02.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.05.2025
Aktien
1 CH0432492467 Alcon AG 2U3
2 CH0110240600... ► Artikel lesen | |
| 28.04. | BioVersys AG: BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025 | 790 | EQS Group (EN) | BioVersys AG
/ Key word(s): Conference
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,226 | -0,27 % | Kaufchance oder weiterer Absturz? Rheinmetall, Evotec und Rohstoff-Highflyer Pasinex Resources im Aktien-Check | Eine der spannendsten Rohstoff-Aktien derzeit ist wohl Pasinex Resources. Obwohl Zink eher im Schatten anderer Rohstoffe steht, entwickelt sich die Aktie mustergültig. Der Fokus auf hochgradige Projekte... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,414 | +0,98 % | BioNxt treibt "Melt in Your Mouth"-Cladribin-Formulierung voran, um die Behandlung von MS-Patienten mit Dysphagie zu verbessern | VANCOUVER, BC / ACCESS Newswire / 9. Dezember 2025 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) meldet Fortschritte bei der Entwicklung einer neuartigen... ► Artikel lesen | |
| MAINZ BIOMED | 1,020 | -2,86 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,508 | -1,05 % | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent... ► Artikel lesen | |
| KUROS BIOSCIENCES | 30,800 | -4,94 % | Kuros Biosciences AG: Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion | Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion
Schlieren (Zürich), Switzerland,... ► Artikel lesen | |
| ABIVAX | 108,80 | -4,39 % | Abivax vor möglicher Übernahme: NBC-Volltreffer liefert +200% Kursgewinn | Nachdem sich die Aktie der französischen Biotechschmiede Abivax in den letzten Monaten schon vervielfachen konnte, verzeichnet sie am heutigen Mittwoch noch einmal einen kräftigen Kurssprung von zeitweise... ► Artikel lesen | |
| BASILEA | 57,80 | +2,85 % | Basilea Pharmaceutica AG: Basilea und Phare Bio gehen Partnerschaft zur Entwicklung eines neuartigen Antibiotikums ein - Kombination von industrieller Expertise und einzigartigen KI-Fähigkeiten | Allschwil, 11. Dezember 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| IDORSIA | 4,475 | +1,24 % | Idorsia Pharmaceuticals Ltd: New Hypertension publication underscores aprocitentan's potential in managing hypertension patients with CKD | New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk... ► Artikel lesen | |
| IMMATICS | 8,510 | -0,53 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| RELIEF THERAPEUTICS | 3,155 | +6,23 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination... ► Artikel lesen | |
| MARINOMED BIOTECH | 18,950 | -0,26 % | Marinomed-Aktie: Ist das eine ganz heiße Wette? | Wenn die Aktie eines Biotech-Unternehmens wie die der österreichischen Marinomed ein Kursdebakel erlebt und binnen fünf Jahren fast -90% an Wert verliert, dann ist das ein für diesen Sektor typisches... ► Artikel lesen | |
| ARGENX | 753,60 | -0,55 % | Stifel raises argenx stock price target to $1,248 on Vyvgart dominance | ||
| BEAM THERAPEUTICS | 27,220 | -1,05 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen | |
| CHROME HOLDING | 0,630 | -18,16 % | 23andMe Research Institute; Troper Wojcicki Philanthropies, Lifebit: Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community | No-cost access available to qualified researchers via open-source federated data platformSAN FRANCISCO, Sept. 06, 2025. Launched in 2024, the Lung Cancer Genetics Study aims to enroll 10,000 individuals... ► Artikel lesen | |
| PHARVARIS | 21,000 | +1,94 % | Der Erfolg von Pharvaris freut Brain Biotech |
BIOVERSYS AG gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,400 (+1,64 %) liegt der Kurs bei 24,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVERSYS AG finden Sie auf Wallstreet Online.